Skip to content

Study · Animal study (in vivo) · 2022

6 results

Binding Domain Characterization of Growth Hormone Secretagogue Receptor.

Sun Y, Ye X, Kennedy H, Smith AGA, Smith RG

Journal of translational internal medicine1 Jun 2022Cited by 5 (Europe PMC)

PMID35959447 (opens in a new tab)PMCIDPMC9328036 (opens in a new tab)DOI10.2478/jtim-2022-0033 (opens in a new tab)PepBankPUB-35959447
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In vivo, MK-0677 showed higher GH secretagogue activity than ghrelin.

    In plain wordsIn animals, MK-0677 stimulated growth hormone activity more than ghrelin.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseGH secretagogue activity
    Study

    n: not reported in source

    Comparator
    ghrelin
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Remarkably, the in vivo GH secretagogue activity is higher with the synthetic agonists MK-0677 and GHS-25 than that of ghrelin.
    1 context sentence
    Summary · context
    We used radiolabeled ligand-binding assay and growth hormone release assay to assess the binding and functional characteristics of GHS-R to synthetic agonists MK-0677 and GHS-25, as well as to endogenous peptide ligand ghrelin.

Studies that did not test the peptide alone5

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 02AnimalNot a test of MK-677 (ibutamoren) aloneAnimal study (in vivo)Mechanism

    In GHS-R knockout mice, synthetic agonist GH secretagogue activity was completely abolished.

    In plain wordsIn mice without GHS-R, synthetic agonists including MK-0677 lost their growth hormone activity.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseGH secretagogue activity after receptor knockout
    Study

    mousen: not reported in source

    GHS-R knockout mice
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Importantly, the activity was completely abolished in GHS-R knockout mice.
    2 context sentences
    Summary · context
    Remarkably, the in vivo GH secretagogue activity is higher with the synthetic agonists MK-0677 and GHS-25 than that of ghrelin.
    Summary · context
    We used radiolabeled ligand-binding assay and growth hormone release assay to assess the binding and functional characteristics of GHS-R to synthetic agonists MK-0677 and GHS-25, as well as to endogenous peptide ligand ghrelin.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  2. 03LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cells)Mechanism

    In GHS-R chimera assays, the C-terminal region, particularly TM6, was critical for ligand-dependent activity.

    In plain wordsIn cells, receptor chimera tests identified the C-terminal region and TM6 as critical for ligand activity.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableC-terminal region and TM6 dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    In GHS-R chimera analysis, we identified the C-terminal region, particularly the transmembrane domain 6 (TM6), to be critical for the ligand-dependent activity.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  3. 04LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cells)Mechanism

    In GHS-R mutagenesis assays, D99 and W276 were essential for ligand binding.

    In plain wordsIn cells, receptor mutation tests identified D99 and W276 as essential for ligand binding.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableD99 and W276 binding dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Our site-directed mutagenesis study further revealed that amino acid residues D99 and W276 in GHS-R are essential for ligand binding.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  4. 05LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cells)Mechanism

    In GHS-R mutagenesis assays, MK-0677 activation depended on E124.

    In plain wordsIn cells, MK-0677 receptor activation depended on E124.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableE124 activation dependence
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    Interestingly, critical residues distinctively interact with different ligands, MK-0677 activation depends on E124, while ghrelin and GHS-25 preferentially interact with F279.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

  5. 06LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Mechanism

    In competitive binding assays, synthetic ligands including MK-0677 showed high affinity for GHS-R.

    In plain wordsIn lab tests, synthetic ligands including MK-0677 bound GHS-R with high affinity.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableBinding affinity
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    We found that the synthetic ligands have high binding affinity to GHS-R in the in vitro competitive binding assay.
    1 context sentence
    Summary · context
    We used radiolabeled ligand-binding assay and growth hormone release assay to assess the binding and functional characteristics of GHS-R to synthetic agonists MK-0677 and GHS-25, as well as to endogenous peptide ligand ghrelin.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.